Combination therapy for extensive stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the use of quaratusugene ozeplasmid in combination with atezolizumab as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who have shown a response to initial treatment. The study consists of two phases: Phase 1 focuses on dose selection, while Phase 2 assesses the safety and efficacy of the recommended dose. Patients must have completed at least three cycles of initial therapy without tumor progression to qualify for this trial. Toxicities will be monitored using established criteria to ensure patient safety throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female aged ≥18 years.
* Documented history of histologically or cytologically confirmed ES-SCLC, prior to starting treatment with the combination of atezolizumab, carboplatin, and etoposide
* Complete Response (CR), Partial Response (PR), or Stable Disease (SD) after receiving at least three cycles, and no more than four cycles, of atezolizumab, carboplatin, and etoposide.
* Eastern Cooperative Oncology Group performance status (ECOG PS) score from 0 to 1.
* Must be ≥28 days beyond major surgical procedures such as thoracotomy, laparotomy, or joint replacement, and must not have evidence of wound dehiscence, active wound infection, or comparable major residual complications of the surgery per Investigator assessment.
* Asymptomatic brain metastases must meet ALL criteria of the following (a-d):

  1. No history of seizures in the preceding six months.
  2. Definitive treatment must be completed ≥21 days prior to enrollment.
  3. Must be off steroids administered because of brain metastases or related symptoms for ≥7 days.
  4. If had previous brain irradiation, post-treatment imaging must demonstrate stability or regression of the brain metastases.
* Absolute neutrophil count (ANC) \>1500/mm3, platelet count \>100,000/mm3 within ≤28 days.
* Adequate renal function documented by serum creatinine of ≤1.5 mg/dL or calculated creatinine clearance \>50 ml/min within ≤28 days.
* Adequate hepatic function as documented by serum bilirubin \<1.5 mg/dL and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X upper limit of normal (ULN) within ≤28 days.
* Stable cardiac condition with a left ventricular ejection fraction ≥40% within ≤28 days.
* If female of childbearing potential (FOCBP), must have negative serum pregnancy test (serum beta-human chorionic gonadotropin \[β-hCG\]) within ≤7 days of first dose.
* FOCBP and non-sterile men who are sexually active with FOCBP must agree to use two forms of contraception including one highly effective and one effective methods beginning ≥2 weeks prior to enrollment through for four months following the last dose of study treatment.
* If male, must agree to no sperm donation during study treatment and for an additional four months following the last dose of study treatment.
* Must have voluntarily signed an informed consent in accordance with institutional policies.

Exclusion Criteria:

* Unable to tolerate atezolizumab treatment, leading to early treatment discontinuation or prolonged/frequent dosage modifications in previous atezolizumab treatment as determined by the Investigator.
* Received prior gene therapy.
* Received prophylactic cranial irradiation or consolidation thoracic radiation.
* Active systemic viral, bacterial, or fungal infection(s) requiring treatment.
* Serious concurrent illness or psychological, familial, sociological, geographical, or other concomitant conditions that, in the opinion of the Investigator, would not permit adequate follow-up and compliance with the study protocol.
* History of autoimmune disease requiring immunosuppression.
* History of myocardial infarction or unstable angina within ≤6 months.
* Known human immunodeficiency virus (HIV) infection or has active hepatitis infection.
* Female who is pregnant or breastfeeding

Where it's running

• Rocky Mountain Cancer Centers, LLP
  Lone Tree, Colorado, United States Recruiting
• Washington University School of Medicine - Siteman Cancer Center
  St Louis, Missouri, United States Recruiting
• Gabrail Cancer Center Research
  Canton, Ohio, United States Recruiting
• Oncology_Hematology Care Clinical Trials, LLC
  Cincinnati, Ohio, United States Recruiting
• Oncology_Hematology Care Clinical Trials, LLC
  Cincinnati, Ohio, United States Recruiting
• Oncology_Hematology Care Clinical Trials, LLC
  Cincinnati, Ohio, United States Recruiting

Study contacts

• Study coordinator: Sr Director, Clinical Operations
• Email: kcombs@genprex.com
• Phone: 1-877-774-GNPX

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• DSP-0390 with Atezolizumab in extensive-stage small cell lung cancer

  This pilot phase Ib study tests whether adding DSP-0390 to maintenance atezolizumab after initial chemo-immunotherapy is safe and shows early signs of activity in people with extensive-stage small cell lung cancer who have not progressed.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07545954

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• BL-M14D1 with Atezolizumab for extensive-stage small cell lung cancer

  This phase 2 trial tests whether adding BL-M14D1 to atezolizumab helps people with extensive-stage small cell lung cancer live longer or well enough to continue treatment.

  Recruiting Phase 2 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07654400

• EASE: A new approach to help adults with advanced cancer cope with fear of progression

  This study tests a written exposure-based coping program to see if it reduces fear of cancer progression and related distress in adults with advanced solid tumors.

  Recruiting at 2 sites University of Colorado, Boulder · Aurora, Colorado and 1 other locations · NCT07636200

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.